Policy, Access, and Value of Immuno-Oncology

Introduction

The Institute for Clinical Immuno-Oncology (ICLIO) is conducting a survey to better understand the barriers and challenges that cancer programs experience in accessing innovative immuno-oncology (I-O) therapies.

Your participation will provide valuable insight that ICLIO and other oncology stakeholders will use to foster discussion around value and access to immunotherapies, with the aim of developing potential solutions.

It should take no more than 5 minutes to complete this survey.

Thank you for making your voice heard.

Question Title

* 1. Contact Information: (All reported data is confidential and will remain anonymous)

Name:

Affiliation:

Email Address:

Question Title

* 2. What is your role at your institution?

Cancer Program Administrator

Medical Oncologist, Hematologist or other with a medical degree

Nurse / Nurse Practitioner

Pharmacist or Pharmacy Technician

Cancer Registry Manager/Coordinator

Other (please specify)

Question Title

* 3. What is your practice setting? (select one)

Hospital-based outpatient cancer center

Freestanding cancer center

Physician-owned oncology practice

Hospital-employed physician oncology practice

Shared operation (an arrangement where resources are shared between two entities, such as private practice and hospital)

Other (please specify)

Section I: Clinical and Policy Issues in Immuno-Oncology (I-O)

Question Title

* 4. To the best of your ability, please rate your staff’s current knowledge with regards to the following clinical characteristics of immuno-oncology (I-O). (1 = little to no knowledge, 5 = very knowledgeable)

	1	2	3	4	5
I-O mechanisms of action	I-O mechanisms of action 1	I-O mechanisms of action 2	I-O mechanisms of action 3	I-O mechanisms of action 4	I-O mechanisms of action 5
I-O indications (specific tumor types treated)	I-O indications (specific tumor types treated) 1	I-O indications (specific tumor types treated) 2	I-O indications (specific tumor types treated) 3	I-O indications (specific tumor types treated) 4	I-O indications (specific tumor types treated) 5
Response assessment to I-O therapy	Response assessment to I-O therapy 1	Response assessment to I-O therapy 2	Response assessment to I-O therapy 3	Response assessment to I-O therapy 4	Response assessment to I-O therapy 5
I-O sequencing considerations (1st line, 2nd line, 3rd line)	I-O sequencing considerations (1st line, 2nd line, 3rd line) 1	I-O sequencing considerations (1st line, 2nd line, 3rd line) 2	I-O sequencing considerations (1st line, 2nd line, 3rd line) 3	I-O sequencing considerations (1st line, 2nd line, 3rd line) 4	I-O sequencing considerations (1st line, 2nd line, 3rd line) 5
Use of I-O biomarkers	Use of I-O biomarkers 1	Use of I-O biomarkers 2	Use of I-O biomarkers 3	Use of I-O biomarkers 4	Use of I-O biomarkers 5

Question Title

* 5. Does your institution have a specific I-O program and/or workspace in place to diagnose and manage immune-related adverse events?

Yes

Not sure